CN114224779A - Eye repair composition and application thereof - Google Patents
Eye repair composition and application thereof Download PDFInfo
- Publication number
- CN114224779A CN114224779A CN202111616014.2A CN202111616014A CN114224779A CN 114224779 A CN114224779 A CN 114224779A CN 202111616014 A CN202111616014 A CN 202111616014A CN 114224779 A CN114224779 A CN 114224779A
- Authority
- CN
- China
- Prior art keywords
- extract
- eye
- parts
- combination
- repair composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008439 repair process Effects 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 229920001661 Chitosan Polymers 0.000 claims abstract description 38
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 37
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 claims abstract description 36
- 229950009883 tocopheryl nicotinate Drugs 0.000 claims abstract description 36
- 229940093497 ergothioneine Drugs 0.000 claims abstract description 35
- 230000000694 effects Effects 0.000 claims abstract description 31
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 10
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000284 extract Substances 0.000 claims description 59
- 238000002360 preparation method Methods 0.000 claims description 31
- 239000000419 plant extract Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 16
- 239000002562 thickening agent Substances 0.000 claims description 15
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 239000006071 cream Substances 0.000 claims description 12
- 239000003906 humectant Substances 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 11
- 239000002738 chelating agent Substances 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 241001530056 Athelia rolfsii Species 0.000 claims description 8
- 239000004359 castor oil Substances 0.000 claims description 8
- 235000019438 castor oil Nutrition 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 8
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 8
- 241001506047 Tremella Species 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 5
- 229940035437 1,3-propanediol Drugs 0.000 claims description 5
- 241000157280 Aesculus hippocastanum Species 0.000 claims description 5
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 5
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 5
- 240000006365 Vitis vinifera Species 0.000 claims description 5
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 5
- 235000010181 horse chestnut Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 5
- 229940064064 purslane extract Drugs 0.000 claims description 5
- 240000008669 Hedera helix Species 0.000 claims description 4
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 4
- 244000141009 Hypericum perforatum Species 0.000 claims description 4
- 229940089116 arnica extract Drugs 0.000 claims description 4
- 229940082431 hamamelis virginiana leaf extract Drugs 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 4
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 4
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 3
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 claims description 3
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 claims description 3
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 240000004246 Agave americana Species 0.000 claims description 2
- 244000118350 Andrographis paniculata Species 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- 240000007049 Juglans regia Species 0.000 claims description 2
- 235000009496 Juglans regia Nutrition 0.000 claims description 2
- 240000001659 Oldenlandia diffusa Species 0.000 claims description 2
- 240000004674 Papaver rhoeas Species 0.000 claims description 2
- 235000007846 Papaver rhoeas Nutrition 0.000 claims description 2
- 241000951473 Schizonepeta Species 0.000 claims description 2
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- FENRSEGZMITUEF-ATTCVCFYSA-E [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OP(=O)([O-])O[C@@H]1[C@@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H](OP(=O)([O-])[O-])[C@H](OP(=O)(O)[O-])[C@H]1OP(=O)([O-])[O-] FENRSEGZMITUEF-ATTCVCFYSA-E 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 claims description 2
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 229940059958 centella asiatica extract Drugs 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 229920013818 hydroxypropyl guar gum Polymers 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 229960005323 phenoxyethanol Drugs 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000001331 rosmarinus officinalis leaf Substances 0.000 claims description 2
- 229940084801 salvia miltiorrhiza root extract Drugs 0.000 claims description 2
- 229940083982 sodium phytate Drugs 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000000213 tara gum Substances 0.000 claims description 2
- 235000010491 tara gum Nutrition 0.000 claims description 2
- 235000020234 walnut Nutrition 0.000 claims description 2
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 claims description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims 1
- 241000131458 Elsholtzia Species 0.000 claims 1
- 241001336859 Lilium japonicum Species 0.000 claims 1
- 244000042664 Matricaria chamomilla Species 0.000 claims 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims 1
- 241000378467 Melaleuca Species 0.000 claims 1
- 239000004909 Moisturizer Substances 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- -1 acetyl chitosamine Chemical compound 0.000 abstract description 22
- 230000037394 skin elasticity Effects 0.000 abstract description 14
- 230000003020 moisturizing effect Effects 0.000 abstract description 13
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 231100000344 non-irritating Toxicity 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 48
- 210000003491 skin Anatomy 0.000 description 34
- 239000002994 raw material Substances 0.000 description 33
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 13
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 235000013793 astaxanthin Nutrition 0.000 description 4
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 4
- 229940022405 astaxanthin Drugs 0.000 description 4
- 239000001168 astaxanthin Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 229960003512 nicotinic acid Drugs 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 3
- 244000247812 Amorphophallus rivieri Species 0.000 description 3
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 3
- 229920002581 Glucomannan Polymers 0.000 description 3
- 229920002752 Konjac Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940046240 glucomannan Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000252 konjac Substances 0.000 description 3
- 235000010485 konjac Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 235000002673 Dioscorea communis Nutrition 0.000 description 2
- 241000544230 Dioscorea communis Species 0.000 description 2
- 241000234435 Lilium Species 0.000 description 2
- 208000035753 Periorbital contusion Diseases 0.000 description 2
- 241000908178 Tremella fuciformis Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000007908 nanoemulsion Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229940054395 tremella fuciformis fruiting body extract Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 229940031723 1,2-octanediol Drugs 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241000208983 Arnica Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 241000521581 Millettia Species 0.000 description 1
- 241000717677 Mosla chinensis Species 0.000 description 1
- 241000219295 Portulaca Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000004263 amino monosaccharides Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to an eye repair composition comprising chitosamine, chitosan mono succinamide, tocopherol nicotinate and ergothioneine and uses thereof. The invention creatively discovers that the composition consisting of the four components of the acetyl chitosamine, the chitosan mono-succinamide, the tocopherol nicotinate and the ergothioneine has remarkable effects on moisturizing skin, particularly eye skin, increasing skin elasticity and eliminating dark circles, and the four components have certain synergistic effect on the effects, are very suitable for eye care products, are mild and non-irritating, and have good stability.
Description
Technical Field
The invention belongs to the technical field of skin care products, relates to an eye repair composition and application thereof, and particularly relates to an eye repair composition with the effects of moisturizing, increasing skin elasticity and eliminating dark circles and application thereof in preparation of an eye skin care product.
Background
The eye skin is the thinnest skin of a human body, sweat glands and sebaceous glands of the skin around the eyes are rarely distributed, elastic fibers and collagen structures are lacked in a dermis layer, nerve fibers and capillary vessels of the skin around the eyes are high in distribution density, and the eye work load is heavy; and as the age increases, lymph and blood circulation becomes slower, blood reflux is insufficient, making the skin darker around the eye and possibly causing hemoglobin to accumulate in the connective tissue, forming dark circles.
CN107184456A discloses a konjac glucomannan eye mask and a preparation method thereof, which utilizes the fact that konjac glucomannan is a natural high molecular polysaccharide and has the characteristics of antibacterial property, thickening property, synergistic property, gel property, caking property, water absorption and film forming property; the added chamomile extract has good antibacterial, antiallergic and skin moistening effects; the tremella extract has excellent moisturizing and water-locking functions, effectively enhances the water-retaining capacity of eyes and the capacity of removing hydroxyl free radicals, prevents the skin of the eyes from aging, and removes wrinkles; the konjac glucomannan eye mask disclosed by the invention is high in nutrient substance adsorption degree, soft and smooth in texture, good in skin affinity, good in fitting property and better in sensory perception.
CN110368355A discloses an astaxanthin-containing nanoemulsion anti-aging eye cream and a preparation method thereof, and the astaxanthin-containing nanoemulsion anti-aging eye cream is composed of the following components in parts by mass: 3-5 parts of honey, 3-5 parts of self-made astaxanthin extract, 4-6 parts of modified nano pearl powder, 2-4 parts of lily essential oil, 3-5 parts of tea saponin, 10-15 parts of natural oil, 5-10 parts of milk, 40-55 parts of water, 0.4-1.7 parts of aloe powder, 2-3 parts of glutathione and 3-5 parts of glycerol. The prepared eye cream has high astaxanthin content, good skin absorption rate, excellent oxidation resistance and wrinkle resistance and high safety.
CN105287320A discloses a mild firming and repairing eye cream and a preparation method thereof, wherein the eye cream comprises: retinol palmitate, palmitoyl oligopeptide, further preferred eye creams include: retinol palmitate, palmitoyl oligopeptide, radix astragali extract, rhizoma Atractylodis Macrocephalae extract, and radix Altaicae extract. The composition has good effects of removing skin wrinkles and the like, is added into a matrix to prepare eye cream, and has mild, compact and repairing effects on the skin of eyes; it also has good stability.
The eye care products disclosed in the prior art mainly have the following defects: the eye care product has relatively single effect, or moisturizes eyes, reduces bags under the eyes, fades dark circles under the eyes or improves wrinkles, all the effects cannot be considered simultaneously, and the eye care product is deficient in all aspects; secondly, although the eye cream can take effect quickly, after the eye cream is used for a period of time, side effects are easy to generate, or new problems such as fat particles are brought, and the eye burden is increased; based on the above, there is a need to develop a mild, safe, fast-acting, high-efficiency moisturizing multi-functional repairing composition which can improve eye microcirculation, increase eye skin elasticity and relieve dark circles and comprehensively solve eye problems.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide an eye repair composition and application thereof, and particularly provides an eye repair composition with the effects of moisturizing, increasing skin elasticity and eliminating dark circles and application thereof in preparation of an eye skin care product.
In order to achieve the purpose, the invention adopts the following technical scheme:
in a first aspect, the present invention provides an ocular repair composition comprising chitosamine, chitosan mono-succinamide, tocopherol nicotinate and ergothioneine.
Among them, acetyl chitosamine (NAG), which is the basic unit of many important polysaccharides in biological cells, has many important physiological functions in organisms and is widely distributed in nature. The hyaluronic acid and the glucuronic acid are both monomers of hyaluronic acid and polymerized monomers of chitin, and exist mainly in the form of chitin; belongs to micromolecular amino monosaccharide, has excellent transdermal absorbability, can improve the hydration of skin, and is a high-quality multifunctional humectant; NAG achieves the whitening effect by inhibiting tyrosinase activity, regulating keratinocyte adhesion and promoting the stripping normalization of stratum corneum.
Wherein, the chitosan group of the chitosan mono-succinamide has good biocompatibility, adhesiveness, degradability, bacteriostasis and plasticity, can promote wound healing and tissue regeneration, has excellent film forming property and can also provide excellent moisturizing effect.
Wherein, the tocopherol nicotinate is ester formed by nicotinic acid and synthetic-alpha-tocopherol, has the multiplication function of the tocopherol and the nicotinic acid, eliminates the toxic and side effect caused by singly using the vitamin E and the nicotinic acid, and has more stable and more durable effect than the combination of the tocopherol and the nicotinic acid.
The L-Ergothioneine (EGT) is a rare natural chiral amino acid, is an important natural active substance in a body, has the functions of resisting oxidation, removing singlet oxygen, hydroxyl free radicals, hypochlorous acid and hydroperoxyl free radicals, detoxifying, maintaining DNA biosynthesis, normal cell growth and cellular immunity, preventing ultraviolet radiation damage, regulating intracellular redox reaction, participating in intracellular energy regulation, cell physiological protection and the like.
The invention creatively discovers that the composition consisting of the four components of the acetyl chitosamine, the chitosan mono-succinamide, the tocopherol nicotinate and the ergothioneine has remarkable effects on moisturizing skin, particularly eye skin, increasing skin elasticity and eliminating dark circles, and the four components have certain synergistic effect on the effects, are very suitable for eye care products, are mild and non-irritating, and have good stability.
Preferably, the ocular repair composition comprises, in parts by weight, 0.01 to 3 parts of chitosamine, 0.001 to 2 parts of chitosan mono-succinamide, 0.001 to 2 parts of tocopherol nicotinate, and 0.0001 to 0.5 part of ergothioneine.
Furthermore, when the four components are combined according to a specific mass ratio, the effects of moisturizing, increasing skin elasticity and eliminating black eyes are more remarkable.
The above weight portions are calculated according to the actual functional components of the chitosan amine, chitosan mono-succinamide, tocopherol nicotinate and ergothioneine contained in the commercial raw materials, and the commercial raw materials also optionally contain any one or the combination of at least two of solvents, fillers, diluents, stabilizers, pH regulators, antibacterial agents, antioxidants or impurities within the allowable range.
The weight parts of the acetylcysteine may be 0.01 parts, 0.05 parts, 0.1 parts, 0.2 parts, 0.5 parts, 1 part, 1.2 parts, 1.5 parts, 1.8 parts, 2 parts, 2.3 parts, 2.5 parts, 3 parts, etc.
The chitosan mono-succinamide may be present in an amount of 0.001 parts, 0.005 parts, 0.01 parts, 0.05 parts, 0.1 parts, 0.2 parts, 0.5 parts, 0.7 parts, 1.0 parts, 1.2 parts, 1.5 parts, 1.8 parts, 2 parts, etc. by weight.
The tocopherol nicotinate may be present in an amount of 0.001 parts, 0.005 parts, 0.01 parts, 0.05 parts, 0.1 parts, 0.2 parts, 0.5 parts, 1 part, 1.2 parts, 1.5 parts, 1.8 parts, 2 parts, etc.
The ergothioneine may be present in an amount of 0.0001 parts, 0.0005 parts, 0.001 parts, 0.005 parts, 0.01 parts, 0.05 parts, 0.1 parts, 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, etc.
Other specific point values within the above numerical ranges can be selected, and are not described in detail herein.
Further preferably, the ocular repair composition comprises 0.1-2 parts by weight of chitosamine, 0.001-0.5 part by weight of chitosan mono succinamide, 0.01-1 part by weight of tocopherol nicotinate and 0.001-0.5 part by weight of ergothioneine.
In a second aspect, the present invention provides the use of an ocular repair composition according to the first aspect in the preparation of a cosmetic product.
Preferably, the cosmetic comprises an eye cream, an eye gel, an eye lotion, an eye essence, an eye mask, an eye patch or an eye gel.
Preferably, the content of the eye repair composition in the cosmetic is 0.1-10% by mass, such as 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, etc., and other specific points in the numerical range can be selected, which is not described herein again.
Preferably, the cosmetic further comprises any one or combination of at least two of a solvent, a humectant, a thickening agent, a solubilizer, a pH regulator, a chelating agent, a preservative, a skin conditioner or a perfume, wherein the combination of at least two of the solvents, the humectant, the thickener and the chelating agent can be selected, and any combination mode can be selected, and the details are not repeated herein.
In a third aspect, the invention provides a multi-effect repairing eye mask, which comprises the following components in percentage by mass: 0.1-6.5% of the eye repair composition, 2-8% of the humectant, 0.05-2% of the thickener, 0.02-1% of the solubilizer, 0.01-0.05% of the chelating agent, 0.05-5% of the preservative, 0.3-2% of the plant extract and water.
The eye repair composition may be present in an amount of 0.1%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, etc. by mass.
The mass percentage of the humectant can be 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8% and the like.
The mass percentage of the thickening agent can be 0.05%, 0.1%, 0.2%, 0.3%, 0.5%, 1%, 2% and the like.
The mass percentage of the solubilizer can be 0.02%, 0.05%, 0.08%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.8%, 1% and the like.
The chelating agent can be 0.01%, 0.02%, 0.03%, 0.04%, 0.05% and the like in percentage by mass.
The preservative can be 0.05%, 0.1%, 0.2%, 0.3%, 0.5%, 1%, 1.5%, 2%, 3%, 4%, 5% and the like by mass.
The mass percentage of the plant extract can be 0.3%, 0.5%, 1%, 1.5%, 2% and the like.
Other specific point values within the above numerical ranges can be selected, and are not described in detail herein.
Preferably, the humectant comprises any one of 1, 3-propylene glycol, hydrolyzed sodium hyaluronate, glycerin, dipropylene glycol, trehalose, or a combination of at least two thereof. The combination of at least two of the above-mentioned compounds, such as the combination of 1, 3-propylene glycol and hydrolyzed sodium hyaluronate, the combination of glycerol and dipropylene glycol, etc., can be selected in any combination manner, and are not repeated herein.
Preferably, the humectant comprises a combination of 1, 3-propanediol, hydrolyzed sodium hyaluronate.
Preferably, the thickener comprises any one or a combination of at least two of sodium hyaluronate, hydrolyzed sclerotium rolfsii gum, tremella entity extract, xanthan gum, tara gum, sodium polyacrylate grafted starch, hydroxypropyl guar gum, ammonium acryloyldimethyl taurate/VP copolymer, sodium polyacrylate or acrylic acid/C10-30 alkanol acrylate crosspolymer. The combination of at least two of the above compounds, such as the combination of sodium hyaluronate and hydrolyzed sclerotium rolfsii gum, the combination of tremella entity extract and xanthan gum, and the like, can be selected in any combination manner, and is not repeated herein.
Preferably, the thickener comprises sodium hyaluronate, hydrolyzed sclerotium rolfsii gum and tremella fuciformis fruiting body extract.
The thickener used in the eye mask according to the present invention is preferably a combination of sodium hyaluronate, hydrolyzed sclerotium rolfsii gum and a tremella fruiting body extract, which is advantageous for improving the stability, skin feel and efficacy of the product.
Preferably, the solubilizer comprises any one or a combination of at least two of polysorbate-20, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, or PPG-26-Butaneth-26.
The combination of at least two of the above mentioned components, such as the combination of polysorbate-20 and PEG-40 hydrogenated castor oil, the combination of PEG-40 hydrogenated castor oil and PEG-60 hydrogenated castor oil, the combination of PEG-60 hydrogenated castor oil and PPG-26-butanol polyether-26, etc., any other combination can be selected, and thus, the detailed description thereof is omitted.
Preferably, the chelating agent comprises disodium EDTA and/or sodium phytate.
Preferably, the preservative comprises any one or a combination of at least two of methylparaben, ethylparaben, phenoxyethanol, 1, 3-propanediol, caprylhydroxamic acid, 1, 2-hexanediol, octanediol, pentanediol or butanediol.
The combination of at least two of the above-mentioned compounds, such as 1, 3-propanediol, caprylhydroxamic acid and 1, 2-hexanediol, octanediol and pentanediol, can be selected, and any other combination method can be selected, and thus, the details are not repeated.
Preferably, the plant extract includes any one or a combination of at least two of a purslane extract, a grape leaf extract, a hypericum perforatum flower/leaf/stem extract, a arnica flower extract, a hamamelis leaf extract, a aesculus hippocastanum extract, an hedera helix extract, a millettia leaf/stem extract, a corn poppy petal extract, a centella asiatica extract, a lilium nipponicum extract, a chamomilla flower extract, a ginger root extract, an agave stem extract, a rosemary leaf extract, a scutellaria baicalensis root extract, an andrographis paniculata extract, a schizonepeta herb extract, a salvia miltiorrhiza root extract, a mosla chinensis flower/leaf/stem extract, an oldenlandia diffusa extract or a walnut kernel extract.
Preferably, the plant extract comprises a combination of purslane extract, grape leaf extract, hypericum perforatum flower/leaf/stem extract, arnica extract, hamamelis virginiana leaf extract, aesculus hippocastanum extract, and hedera helix extract.
In a fourth aspect, the present invention provides a method for preparing the multi-effect prosthetic eye mask as described in the third aspect, the method comprising:
(1) mixing and stirring water and a chelating agent, heating, and preserving heat to obtain a phase A;
mixing and stirring the thickening agent, the humectant and the preservative to obtain a phase B;
mixing and stirring the solubilizer and the tocopherol nicotinate in the eye-care composition to obtain a phase D;
(2) mixing the phase A, the phase B and the phase D with the chitosamine, ergothioneine, chitosan mono-succinamide and plant extract in the eye repair composition, and homogenizing to obtain the eye repair composition.
Preferably, the heating in step (1) means heating to 75-85 deg.C, such as 75 deg.C, 78 deg.C, 80 deg.C, 81 deg.C, 82 deg.C, 83 deg.C, 84 deg.C, 85 deg.C, etc.; the heat preservation time is 5-30min, such as 5min, 10min, 15min, 20min, 22min, 25min, 28min, 30min, etc.
Preferably, the homogenization in step (2) is carried out at 40-45 ℃, such as 40 ℃, 41 ℃, 42 ℃, 43 ℃, 44 ℃, 45 ℃ and the like.
Other specific point values within the above numerical ranges can be selected, and are not described in detail herein.
In a fifth aspect, the present invention provides a multi-effect prosthetic eye mask comprising the multi-effect prosthetic eye essence and mask cloth according to the fourth aspect.
Compared with the prior art, the invention has the following beneficial effects:
the invention creatively discovers that the composition consisting of the four components of the acetyl chitosamine, the chitosan mono-succinamide, the tocopherol nicotinate and the ergothioneine has remarkable effects on moisturizing skin, particularly eye skin, increasing skin elasticity and eliminating dark circles, and the four components have certain synergistic effect on the effects, are very suitable for eye care products, are mild and non-irritating, and have good stability.
Detailed Description
To further illustrate the technical means and effects of the present invention, the following further describes the technical solution of the present invention with reference to the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
The following parts by weight of the chitosamine, chitosan mono-succinamide, tocopherol nicotinate and ergothioneine are calculated according to the actual content of the effective components in the commercial raw materials, and the commercial raw materials optionally contain any one or the combination of at least two of solvents, fillers, diluents, stabilizers, pH regulators, antibacterial agents, antioxidants or impurities within the allowable range.
The following examples, comparative examples, application examples and comparative application examples relate to the production of acetylcysteine from Hyafactor, a model of Hyafactor available from Huaxi organismsTM-the product of NAG; the chitosan mono-succinamide is obtained from KATAKURA&CO-OP AGRI CORP, MOISTFINE LIQUID; the tocopherol nicotinate is from Shanghai Keqin of type
-the product of VEN; the ergothioneine is originated from Shanghai Keqin of the type
-3P products; the hydrolyzed sclerotium rolfsii gum is derived from a product which is purchased from Super Vision Bio-Tech int.Ltd and has the model number of macro HGS; the Tremella fuciformis sporophore extract is obtained from Tremella heteropolysaccharide (WSK) product purchased from Shanghai Huiwen Biotechnology corporation; sodium hyaluronate was derived from a product available from Huaxi organisms in the form of Hyblom sodium hyaluronate (HA-T); the hydrolyzed sodium hyaluronate is derived from Huaxi organism and is super-active hyaluronic acid (Ximin repair)TM) The product of (1); the plant extract I (mainly effective components including grape leaf extract, flos Hyperici perforati/leaf/stem extract, Arnica extract, Hamamelis virginiana leaf extract, Aesculus hippocastanum extract, and caulis Hederae sinensis extract) is derived from product of Laboratoies setanic Innovatoons with model number of ANTI-redESS COMPLEX 261 UP; plant EXTRACT II (the main functional component is purslane EXTRACT) is derived from a product purchased from SK bioland and having model number Portulaca EXTRACT.
Example 1
The embodiment provides an eye repair composition, which comprises the following functional components in parts by weight: 1 part of acetyl chitosamine, 0.08 part of chitosan mono-succinamide, 0.5 part of tocopherol nicotinate and 0.01 part of ergothioneine. The preparation method comprises the step of uniformly mixing various commercially available raw material products.
Example 2
The embodiment provides an eye repair composition, which comprises the following functional components in parts by weight: 0.5 part of acetyl chitosamine, 0.01 part of chitosan mono-succinamide, 0.1 part of tocopherol nicotinate and 0.003 part of ergothioneine. The preparation method comprises the step of uniformly mixing various commercially available raw material products.
Example 3
The embodiment provides an eye repair composition, which comprises the following functional components in parts by weight: 2 parts of acetyl chitosamine, 0.5 part of chitosan mono-succinamide, 1 part of tocopherol nicotinate and 0.5 part of ergothioneine. The preparation method comprises the step of uniformly mixing various commercially available raw material products.
Comparative example 1
The comparative example provides an eye repair composition, which comprises the following functional components in parts by weight: 0.08 part of chitosan mono-succinamide, 0.5 part of tocopherol nicotinate and 0.01 part of ergothioneine. The preparation method comprises the step of uniformly mixing various commercially available raw material products.
Comparative example 2
The comparative example provides an eye repair composition, which comprises the following functional components in parts by weight: 1 part of acetyl chitosamine, 0.5 part of tocopherol nicotinate and 0.01 part of ergothioneine. The preparation method comprises the step of uniformly mixing various commercially available raw material products.
Comparative example 3
The comparative example provides an eye repair composition, which comprises the following functional components in parts by weight: 1 part of acetyl chitosamine, 0.08 part of chitosan mono succinamide and 0.01 part of ergothioneine. The preparation method comprises the step of uniformly mixing various commercially available raw material products.
Comparative example 4
The comparative example provides an eye repair composition, which comprises the following functional components in parts by weight: 1 part of acetyl chitosamine, 0.08 part of chitosan mono-succinamide and 0.5 part of tocopherol nicotinate. The preparation method comprises the step of uniformly mixing various commercially available raw material products.
Comparative example 5
The present comparative example provides an efficacy material comprising a single ingredient, acetylcysteine.
Comparative example 6
The present comparative example provides an efficacy material comprising chitosan mono-succinamide as a single ingredient.
Comparative example 7
The present comparative example provides an effect substance comprising a single component tocopherol nicotinate.
Comparative example 8
This comparative example provides an effect material comprising ergothioneine as a single ingredient.
Application example 1
The application example provides a multi-effect eye repair essence which comprises the following components in parts by weight:
the preparation method comprises the following steps:
(1) adding the phase A raw material into a clean emulsifying pot, stirring and heating to 85 ℃, preserving heat for 20 minutes, and starting cooling water to cool;
(2) respectively pre-mixing and uniformly stirring the phase B raw material and the phase D raw material for later use;
(3) when the temperature in the emulsifying pot is reduced to below 45 ℃, adding the C-phase raw material and the pre-treated B-phase and D-phase raw materials into the emulsifying pot, and stirring and dispersing uniformly;
(4) and continuously cooling to 38 ℃, sampling, observing and testing, and discharging after the product is qualified.
Application example 2
The application example provides a multi-effect eye repair essence, the formula of which is only different from that of application example 1 in that the contents of the acetyl chitosamine, the chitosan mono-succinamide, the tocopherol nicotinate and the ergothioneine are respectively 1%, 0.02%, 0.2% and 0.006%, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Application example 3
The application example provides a multi-effect eye repair essence, the formula of which is only different from that of application example 1 in that the contents of the acetyl chitosamine, the chitosan mono-succinamide, the tocopherol nicotinate and the ergothioneine are respectively 0.5%, 0.3%, 0.5% and 0.005%, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Comparative application example 1
The present comparative example provides an eye essence whose formulation is different from application example 1 only in that: does not contain the acetyl chitosamine, and the reduced mass is proportionally distributed on the content of chitosan mono-succinamide, the content of tocopherol nicotinate and the content of ergothioneine, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Comparative application example 2
The present comparative example provides an eye essence whose formulation is different from application example 1 only in that: does not contain chitosan mono-succinamide, and the reduced mass is proportionally distributed on the content of the acetyl chitosamine, the content of the tocopherol nicotinate and the content of the ergothioneine, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Comparative application example 3
The present comparative example provides an eye essence whose formulation is different from application example 1 only in that: does not contain tocopherol nicotinate, and the reduced mass is proportionally distributed on the content of the acetyl chitosamine, the content of the chitosan mono-succinamide and the content of the ergothioneine, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Comparative application example 4
The present comparative example provides an eye essence whose formulation is different from application example 1 only in that: does not contain ergothioneine, the reduced mass is proportionally distributed to the content of the acetyl chitosamine, the content of the chitosan mono-succinamide and the content of the tocopherol nicotinate, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Comparative application example 5
The present comparative example provides an eye essence whose formulation is different from application example 1 only in that: does not contain ergothioneine, chitosan mono-succinamide and tocopherol nicotinate, and the content of the acetyl chitosamine is 1.59 percent, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Comparative application example 6
The present comparative example provides an eye essence whose formulation is different from application example 1 only in that: does not contain the acetyl chitosamine, ergothioneine and tocopherol nicotinate, and the content of the chitosan mono-succinamide is 1.59 percent, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Comparative application example 7
The present comparative example provides an eye essence whose formulation is different from application example 1 only in that: does not contain the acetyl chitosamine, ergothioneine and chitosan mono succinamide, and the content of the tocopherol nicotinate is 1.59 percent, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Comparative application example 8
The present comparative example provides an eye essence whose formulation is different from application example 1 only in that: does not contain the acetyl chitosamine, the tocopherol nicotinate and the chitosan mono-succinamide, the content of the ergothioneine is 1.59 percent, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Application example 4
The application example provides a multi-effect eye repair essence, and the formula of the eye repair essence is different from that of the eye repair essence in the application example 1 only in that the eye repair essence does not contain hydrolyzed sclerotium rolfsii gum, the content of the tremella fuciformis entity extract is 0.3%, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Application example 5
The application example provides a multi-effect eye repair essence, and the formula of the eye repair essence is different from that of the eye repair essence in application example 1 only in that the eye repair essence does not contain a tremella fuciformis fruiting body extract, the content of hydrolyzed sclerotium rolfsii gum is 0.3%, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Application example 6
The application example provides a multi-effect eye repair essence, and the formula of the essence is different from that of application example 1 only in that the essence does not contain a plant extract I, the content of a plant extract II is 1%, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Application example 7
The application example provides a multi-effect eye repair essence, and the formula of the essence is different from that of application example 1 only in that the essence does not contain a plant extract II, the content of the plant extract I is 1%, and other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Comparative application example 9
This comparative application example provides an ophthalmic mask which was prepared from the raw materials that differed from application example 1 only in that the ocular repair composition of example 1 was not included, with the reduced amount being made up with water. Other raw materials and contents are kept unchanged. The preparation process is as in application example 1.
Test example 1
Skin safety test:
placing the eye mask products prepared in application examples 1-7 in a spot tester, sticking the spot tester with the test substance on the bent side of the forearm of a tested person (30) and lightly pressing with the palm to uniformly stick the eye mask product on the skin for 24 hours; the skin irritation and sensitization were observed according to table 1 (skin closed patch test skin response grading standard) 30min, 24 hours, and 48 hours after removal of the test substance patch, respectively, and the observation results were recorded.
TABLE 1
The results show that no adverse skin reactions occur in the products of application examples 1 to 7, which indicates that the eye repair composition and the eye mask of the invention are safe and non-irritant to skin.
Test example 2
And (4) testing the moisturizing effect:
160 subjects were selected, the age range was 28 to 40 years, the average age was 34 years, and the subjects were randomly divided into 16 groups, each group of subjects was externally applied with the same amount of the eye film products of application examples 1 to 7 of the present invention and comparative application examples 1 to 9, eye skin moisture content MMV of the subjects before and after use was measured with a corneometer cm 825 skin moisture content tester, the skin moisture content increase rate was calculated according to the following formula, and the average value was taken, and the test results are shown in table 2 below.
MMV in the formula0MMV for pre-use skin; MMVtIs the skin MMV t period after use.
TABLE 2
As can be seen from the data in Table 2: the eye repair composition and the eye mask have excellent moisturizing effect, the acetylcysteine, the chitosan mono-succinamide, the tocopherol nicotinate and the ergothioneine have synergistic effect on improving the moisturizing performance of the product, and the combination mode of the plant extracts and the combination mode of the thickening agent influence the moisturizing performance of the product.
Test example 3
Skin elasticity and melanin testing:
(1) testing an instrument: skin elasticity tester (MPA580, CK Electronic GmH, germany); skin melanin and heme tester (Mexameter MX18, CK Electronic GmH, germany);
(2) test samples: eye film products of application examples 1-11 and comparative application examples 1-9;
(3) the test requirements are as follows: room temperature 20 + -2 deg.C, Relative Humidity (RH)50 + -5%;
(4) the test method comprises the following steps: 80 volunteers with the skin around the eyes of 35-50 years old and having the problems of black eye circles, fine wrinkles and the like are selected and randomly divided into 16 groups, 5 persons in each group use the eye mask products of application examples 1-7 and comparative application examples 1-9 respectively, and the use method is to use the eye mask products after cleaning the face and use the eye mask products three times per week. The skin elasticity of the eyes was measured with a skin elasticity tester MPA580, the skin melanin value and the red pigment value of the eyes of the volunteers were measured with a Mexameter MX18, 3 points were measured at the periphery of the eyes, and the average value was taken, before and 30 days after use, respectively.
(5) Evaluation criteria:
the wrinkle removing effect is as follows: the skin elasticity of the eyes is tested by a skin elasticity tester MPA580, and the higher the value is, the better the surface skin elasticity is. The rate of increase in the elasticity of the skin is calculated using the following formula: the elastic increase rate (after use value-before use value)/before use value × 100%. The greater the rate of rise in elasticity, the better the wrinkle-removing effect.
Eliminating black eye effect: the effect of eliminating dark circles was judged by measuring the change rate of melanin before and after use, which is (pre-use melanin value-post-use melanin value)/pre-use melanin value × 100%. The greater the rate of change of melanin, the better the effect of eliminating dark circles. The results are shown in Table 3:
TABLE 3
| Sample (I) | Elastic lifting rate | Reduction rate of melanin |
| Application example 1 | 28.4％ | 14.7％ |
| Application example 2 | 24.6％ | 13.4％ |
| Application example 3 | 26.4％ | 13.8％ |
| Application example 4 | 27.3％ | 14.1％ |
| Application example 5 | 27.1％ | 13.5％ |
| Application example 6 | 23.6％ | 11.3％ |
| Application example 7 | 24.9％ | 12.2％ |
| Comparative application example 1 | 17.4％ | 9.8％ |
| Comparative application example 2 | 16.1％ | 7.5％ |
| Comparative application example 3 | 15.3％ | 7.6％ |
| Comparative application example 4 | 16.1％ | 8.3％ |
| Comparative application example 5 | 4.3％ | 2.4％ |
| Comparative application example 6 | 5.9％ | 3.1％ |
| Comparative application example 7 | 8.4％ | 3.5％ |
| Comparative application example 8 | 6.7％ | 4.3％ |
| Comparative application example 9 | 2.2％ | 0.3％ |
As can be seen from the data in Table 3: the eye repair composition and the eye mask have excellent effects of increasing the elasticity of eye skin, fading fine lines and eliminating dark circles, the chitosan mono-succinamide, the tocopherol nicotinate and the ergothioneine have a synergistic effect on the aspect of improving the effects of the product, and meanwhile, the combination mode of the plant extracts and the combination mode of the thickening agent can also influence the effects of the product.
The applicant states that the present invention is described by the above examples to describe an eye repair composition of the present invention and its application, but the present invention is not limited to the above examples, that is, it does not mean that the present invention must be implemented by the above examples. It should be understood by those skilled in the art that any modification of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.
Claims (10)
1. An ocular repair composition comprising chitosamine, chitosan mono-succinamide, tocopherol nicotinate, and ergothioneine.
2. The ocular repair composition of claim 1, wherein the ocular repair composition comprises, in parts by weight, 0.01 to 3 parts of chitosamine, 0.001 to 2 parts of chitosan mono succinamide, 0.001 to 2 parts of tocopherol nicotinate, and 0.0001 to 0.5 parts of ergothioneine.
3. The ocular repair composition of claim 2 comprising, in parts by weight, 0.1 to 2 parts of chitosamine, 0.001 to 0.5 parts of chitosan mono succinamide, 0.01 to 1 part of tocopherol nicotinate, and 0.001 to 0.5 parts of ergothioneine.
4. Use of an ocular repair composition according to any of claims 1 to 3 for the preparation of a cosmetic product.
5. The use of claim 4, wherein the cosmetic comprises an eye cream, eye gel, eye cream, eye essence, eye mask, eye patch or eye gel;
preferably, the content of the eye repair composition in the cosmetic is 0.1-10% by mass;
preferably, the cosmetic also comprises any one or combination of at least two of a solvent, a humectant, a thickening agent, a solubilizer, a pH regulator, a chelating agent, a preservative, a skin conditioning agent or a essence.
6. The multi-effect eye repair essence is characterized by comprising the following components in percentage by mass: the ocular repair composition of any one of claims 1-3, 0.1-6.5%, humectant 2-8%, thickener 0.05-2%, solubilizer 0.02-1%, chelating agent 0.01-0.05%, preservative 0.05-5%, plant extract 0.3-2%, water.
7. The multiple effect eye repair serum of claim 6, wherein the thickener comprises any one or a combination of at least two of sodium hyaluronate, hydrolyzed sclerotium rolfsii gum, tremella sporophore extract, xanthan gum, tara gum, sodium polyacrylate grafted starch, hydroxypropyl guar gum, ammonium acryloyldimethyl taurate/VP copolymer, sodium polyacrylate or acrylic acid/C10-30 alkanol acrylate crosspolymer;
preferably, the thickening agent comprises sodium hyaluronate, hydrolyzed scleroderma, and tremella sporophore extract;
preferably, the humectant comprises any one or a combination of at least two of 1, 3-propylene glycol, hydrolyzed sodium hyaluronate, glycerol, dipropylene glycol and trehalose;
preferably, the moisturizer comprises a combination of 1, 3-propanediol, hydrolyzed sodium hyaluronate;
preferably, the plant extract includes any one or a combination of at least two of purslane extract, grape leaf extract, hypericum perforatum flower/leaf/stem extract, arnica extract, hamamelis virginiana leaf extract, aesculus hippocastanum extract, hedera helix extract, melaleuca mulosa leaf/stem extract, corn poppy petal extract, centella asiatica extract, lilium japonicum extract, chamomile flower extract, ginger root extract, agave stem extract, rosemary leaf extract, scutellaria baicalensis root extract, andrographis paniculata extract, schizonepeta extract, salvia miltiorrhiza root extract, elsholtzia/leaf/stem extract, oldenlandia diffusa extract or walnut kernel extract;
preferably, the plant extract comprises a combination of purslane extract, grape leaf extract, hypericum perforatum flower/leaf/stem extract, arnica extract, hamamelis virginiana leaf extract, aesculus hippocastanum extract, and hedera helix extract;
preferably, the solubilizer comprises any one or a combination of at least two of polysorbate-20, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil or PPG-26-buthaneth-26;
preferably, the chelating agent comprises disodium EDTA and/or sodium phytate;
preferably, the preservative comprises any one or a combination of at least two of methylparaben, ethylparaben, phenoxyethanol, 1, 3-propanediol, caprylhydroxamic acid, 1, 2-hexanediol, octanediol, pentanediol or butanediol.
8. The multi-effect eye repair essence according to claim 6 or 7, wherein the preparation method comprises:
(1) mixing and stirring water and a chelating agent, heating, and preserving heat to obtain a phase A;
mixing and stirring the thickening agent, the humectant and the preservative to obtain a phase B;
mixing and stirring the solubilizer and the tocopherol nicotinate in the eye-care composition to obtain a phase D;
(2) mixing the phase A, the phase B and the phase D with the chitosamine, ergothioneine, chitosan mono-succinamide and plant extract in the eye repair composition, and homogenizing to obtain the eye repair composition.
9. The method for preparing the multi-effect restoration eye mask according to claim 8, wherein the heating in the step (1) is heating to 75-85 ℃, and the heat preservation time is 5-30 min;
preferably, the homogenization of step (2) is carried out at 40-45 ℃.
10. A multipurpose prosthetic eye mask, comprising the multipurpose prosthetic eye essence of claim 6 or 7 and a mask cloth.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111616014.2A CN114224779A (en) | 2021-12-27 | 2021-12-27 | Eye repair composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111616014.2A CN114224779A (en) | 2021-12-27 | 2021-12-27 | Eye repair composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114224779A true CN114224779A (en) | 2022-03-25 |
Family
ID=80763591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111616014.2A Pending CN114224779A (en) | 2021-12-27 | 2021-12-27 | Eye repair composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114224779A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114668682A (en) * | 2022-04-29 | 2022-06-28 | 广州睿森生物科技有限公司 | Moisturizing and skin-brightening composition and application thereof |
| CN115212134A (en) * | 2022-07-27 | 2022-10-21 | 哈尔滨敷尔佳科技股份有限公司 | Anti-aging nano composition, preparation method and application thereof |
| CN116077375A (en) * | 2023-01-03 | 2023-05-09 | 广州睿森生物科技有限公司 | Multiple chitosan soothing composition and application thereof |
| EP4257113A1 (en) * | 2022-04-08 | 2023-10-11 | Colgate-Palmolive Company | Skin care compositions comprising vitamin e and vitamin b3 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160120781A1 (en) * | 2014-11-03 | 2016-05-05 | Stella & Dot Llc | Skincare formulations and regimens |
| CN108969444A (en) * | 2018-09-19 | 2018-12-11 | 陈洁珍 | One kind removing black eye, crease-resistant Firm anti-age corrective eye treatment cream and preparation method thereof |
| CN110664689A (en) * | 2019-10-30 | 2020-01-10 | 张瀚文 | Eye cream preparation with flexible nano-liposome as carrier and preparation method thereof |
| CN110917061A (en) * | 2019-12-26 | 2020-03-27 | 华熙生物科技股份有限公司 | Composition containing ergothioneine extracting solution, brown rice fermentation filtrate and acetyl chitosamine and application thereof |
| CN111728886A (en) * | 2020-07-13 | 2020-10-02 | 植物医生(广东)生物科技有限公司 | Whitening composition and preparation method and application thereof |
| CN112315839A (en) * | 2020-10-21 | 2021-02-05 | 广州品域美妆创新科技有限公司 | Brightening and anti-saccharification composition containing carnosine and ergothioneine and application thereof |
| CN113797136A (en) * | 2021-10-27 | 2021-12-17 | 北京旋光普利生物医药科技开发有限公司 | Combined preparation of anti-wrinkle-reducing eye cream emulsion |
-
2021
- 2021-12-27 CN CN202111616014.2A patent/CN114224779A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160120781A1 (en) * | 2014-11-03 | 2016-05-05 | Stella & Dot Llc | Skincare formulations and regimens |
| CN108969444A (en) * | 2018-09-19 | 2018-12-11 | 陈洁珍 | One kind removing black eye, crease-resistant Firm anti-age corrective eye treatment cream and preparation method thereof |
| CN110664689A (en) * | 2019-10-30 | 2020-01-10 | 张瀚文 | Eye cream preparation with flexible nano-liposome as carrier and preparation method thereof |
| CN110917061A (en) * | 2019-12-26 | 2020-03-27 | 华熙生物科技股份有限公司 | Composition containing ergothioneine extracting solution, brown rice fermentation filtrate and acetyl chitosamine and application thereof |
| CN111728886A (en) * | 2020-07-13 | 2020-10-02 | 植物医生(广东)生物科技有限公司 | Whitening composition and preparation method and application thereof |
| CN112315839A (en) * | 2020-10-21 | 2021-02-05 | 广州品域美妆创新科技有限公司 | Brightening and anti-saccharification composition containing carnosine and ergothioneine and application thereof |
| CN113797136A (en) * | 2021-10-27 | 2021-12-17 | 北京旋光普利生物医药科技开发有限公司 | Combined preparation of anti-wrinkle-reducing eye cream emulsion |
Non-Patent Citations (1)
| Title |
|---|
| 电子凭证-国产非特殊用途化妆品备案信息服务平台: "珀莱雅晶萃焕妍臻采弹力紧致眼霜", 《FTBA.NMPA.GOV.CN:8181/FTBAN/ITOWNET/HZP_BA/FW/PZ.JSP?PROCESSID=20141106164952O5HCL&NID=20141106164952O5HCL》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4257113A1 (en) * | 2022-04-08 | 2023-10-11 | Colgate-Palmolive Company | Skin care compositions comprising vitamin e and vitamin b3 |
| WO2023196200A1 (en) * | 2022-04-08 | 2023-10-12 | Colgate-Palmolive Company | Skin care compositions comprising vitamin e and vitamin b3 |
| WO2023196194A3 (en) * | 2022-04-08 | 2023-11-16 | Colgate-Palmolive Company | Skin care compositions comprising vitamin e and vitamin b3 |
| EP4257112A3 (en) * | 2022-04-08 | 2024-01-03 | Colgate-Palmolive Company | Skin care compositions comprising vitamin e and vitamin b3 |
| US11938212B2 (en) | 2022-04-08 | 2024-03-26 | Colgate-Palmolive Company | Skin care compositions |
| CN114668682A (en) * | 2022-04-29 | 2022-06-28 | 广州睿森生物科技有限公司 | Moisturizing and skin-brightening composition and application thereof |
| CN115212134A (en) * | 2022-07-27 | 2022-10-21 | 哈尔滨敷尔佳科技股份有限公司 | Anti-aging nano composition, preparation method and application thereof |
| CN116077375A (en) * | 2023-01-03 | 2023-05-09 | 广州睿森生物科技有限公司 | Multiple chitosan soothing composition and application thereof |
| CN116077375B (en) * | 2023-01-03 | 2024-08-20 | 广州睿森生物科技有限公司 | Multiple chitosan soothing composition and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114224779A (en) | Eye repair composition and application thereof | |
| CN107334726B (en) | Acne-removing composition and preparation method and application thereof | |
| CN109453087B (en) | Whitening skin-penetrating lotion, preparation method thereof and whitening cosmetic additive | |
| CN110731974B (en) | Skin external composition with enhanced anti-inflammatory efficacy | |
| CN105902408B (en) | Cosmetic composition containing brown alga and red algae essence | |
| CN110585048B (en) | Composition with anti-saccharification and anti-oxidation functions and application thereof | |
| CN110664650A (en) | Multi-effect skin care composition and essence and preparation method thereof | |
| CN109350579B (en) | Whitening cosmetic additive, whitening skin-refreshing lotion and preparation method thereof | |
| CN115487348A (en) | Composition containing recombinant humanized collagen and preparation method and application thereof | |
| CN114522129A (en) | Moisturizing, firming and repairing composition, cosmetic and preparation method | |
| CN111973481A (en) | Blue ketone peptide repair essence and preparation method thereof | |
| CN110037976B (en) | Moisturizing and anti-inflammatory composition and skin care product | |
| CN114748396A (en) | Soothing and moisturizing composition suitable for desert muscles and preparation method and application thereof | |
| CN111973486A (en) | Ceramide moisturizing and moisture-keeping cream and preparation method thereof | |
| CN111973501A (en) | Ceramide activation milk and preparation method thereof | |
| CN112773761B (en) | Cosmetic composition, essence and preparation method thereof | |
| CN106377463A (en) | Hydrating toner composition free from preservatives | |
| CN107802545A (en) | A kind of anti-oxidant and lightening compositions and the skin care item containing said composition | |
| CN109394622B (en) | Leg slimming essence lotion | |
| CN115778870A (en) | Anti-wrinkle anti-aging composition and preparation method and application thereof | |
| CN114288201B (en) | Composition for removing pouch and fading black eye, and preparation method and application thereof | |
| CN116350542A (en) | Moisturizing composition and application thereof as well as moisturizing essence | |
| CN116035987A (en) | Small molecule peptide multielement composition and skin care product containing same | |
| CN115350128A (en) | Skin-brightening anti-wrinkle composition and preparation method and application thereof | |
| CN114344211A (en) | Moisturizing and stabilizing composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220325 |
|
| RJ01 | Rejection of invention patent application after publication |